Henlius’s Serplulimab Could Offer First Chemo-Free Adjuvant Option In Perioperative Gastric Cancer

 
• By Dexter Jie Yan
  
Roughly two-thirds of the annually 400,000 new gastric cancer cases in China will be suitable for perioperative treatments. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D